Drug Trial Radar · NCT05458219
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
470
Planned (sponsor's estimate)
Start
Oct 26, 2022
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Fortvita Biologics (USA)Inc.; TigerMed
- First posted
- Jul 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in different countries or regions such as China, Australia and US. There are three parts in phase Ia. Part 1 includes dose escalation and expansion phase and part 2 is designed for dose optimization for IBI343 monotherapy. Part 3 1L G/GEJ AC and 1L PDAC cohorts will include an initial safety lead-in stage to confirm the tolerability of IBI343 in combination with chemotherapy in 1L PDAC and G/GEJ AC, followed by a randomized dose-optimization stage designed to further characterize safety, pharmacokinetics, and preliminary efficacy to inform selection of the recommended Phase 3 dose.
Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
Interventions
IBI343Drug
IBI343 will be administered intravenously (IV) on Day 1 of every 21-day cycle.
FOLFIRINOX/mFOLFIRINOXDrug
FOLFIRINOX/mFOLFIRINOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days).
mFOLFOXDrug
mFOLFOX will be administered IV Q2W on Days 1-3 every 2 weeks (14 days) in each cycle after IBI343
IBI343Drug
IBI343 will be administered IV Q2W on Day1 (14 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events(AEs), treatment emergent adverse event (TEAEs),serious adverse events (SAEs)Time frame: Up to 90 days after the last administration
- Dose-limiting Toxicity (DLT)Time frame: 21 days after the first dose of IBI343
- To determine RP2D of IBI343.Time frame: Up to 2 years
- ORR assessed by the investigator based on RECIST version 1.1.Time frame: Up to 2 years
- Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 2 years
- Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
- Objective response rate (ORR)Time frame: ORR is defined as the proportion of participants with a completeresponse (CR) or partial response (PR)
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal vital signsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
- Number of participants with abnormal laboratory tests resultsTime frame: Through study completion, up to 2 years
Locations
39 sites in 3 countries. Site status is shown where the registry gives one.
Next Oncology-Austin
Austin, Texas · Recruiting
Next Oncology-Dallas
Irving, Texas · Recruiting
Next Oncology-San Antonio
San Antonio, Texas · Recruiting
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia · Recruiting
Cancer Care Wollongong
Wollongong, New South Wales, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Active not recruiting
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia · Recruiting
Anhui Cancer Hospital
Hefei, Anhui, China · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Tumor Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen Memorial Hospital Sun Yat-Sen university
Guangzhou, Guangzhou, China · Recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangzhou, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Ningxia Medical University General Hospital
Yinchuan, Ningxia, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Jinan Central Hospital
Jinan, Shandong, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Jining First People's Hospital
Jining, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Ningbo Medical Center Li Huili Hospital
Ningbo, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.